Tirzepatide
Dual GLP-1 + GIP therapy, prescribed and monitored by licensed providersLicensed US provider reviewed
A dual incretin therapy prescribed for weight management. Tirzepatide activates two pathways, GIP and GLP-1, to reduce appetite, guided by licensed providers from intake to ongoing care. Individual results vary.
Licensed provider oversight US pharmacy delivery Dose escalation available
Reviewed by a licensed US provider.
Your assessment is reviewed by a licensed clinician. Approved treatments ship from a licensed US compounding pharmacy in plain, discreet packaging.